Checklist for studies of HIV drug resistance prevalence or incidence: rationale and recommended use

Affiliations

¹ Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada; Department of Anesthesia, McMaster University, Hamilton, ON, Canada; Department of Pediatrics, McMaster University, Hamilton, ON, Canada; Biostatistics Unit, Father Sean O'Sullivan Research Centre, St Joseph's Healthcare, Hamilton, ON, Canada; Centre for Development of Best Practices in Health, Yaoundé Central Hospital, Yaoundé, Cameroon; Department of Global Health, Stellenbosch University, Cape Town, South Africa. Electronic address: mbuagblc@mcmaster.ca.
² Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada.
³ McGill Centre for Viral Diseases, Lady Davis Institute for Medical Research, Montréal, QC, Canada; Department of Microbiology and Immunology, McGill University, Montréal, QC, Canada; Department of Medicine, Surgery, and Infectious Disease, McGill University, Montréal, QC, Canada.
⁴ Hospital General de Agudos Dr. Cosme Argerich, Buenos Aires, Argentina; Helios Salud, Buenos Aires, Argentina.
⁵ Infectious Diseases Department, Fatouma Bourguiba University Hospital, Monastir, Tunisia.
⁶ Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada; Yale University School of Nursing, Yale University, West Haven, CT, USA; Centre for Urban Health Solutions, St Michael's Hospital, Toronto, ON, Canada.
⁷ HIV-1 Molecular Epidemiology Laboratory, Microbiology and Parasitology Department, Hospital Ramón y Cajal-IRYCIS and CIBEREsp-RITIP, Madrid, Spain.
⁸ Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel; Central Virology Laboratory, Ministry of Health and Sheba Medical Centre, Tel-Hashomer, Israel.
⁹ Data First Consulting, Sebastopol, CA, USA.
¹⁰ Department of Experimental Medicine, University of Rome 'Tor Vergata', Rome, Italy.
¹¹ Instituto Nacional de Enfermedades Respiratorias, Mexico City, Mexico; Centro de Investigaciones en Enfermedades Infecciosas, Mexico City, Mexico.
¹² Chantal BIYA International Reference Centre for Research on HIV/AIDS Prevention and Management, Yaoundé, Cameroon; Faculty of Health Science, University of Buea, Buea, Cameroon; National HIV Drug Resistance Working Group, Ministry of Public Health, Yaoundé, Cameroon.
¹³ Institute for Global Health, University College London, London, UK.
¹⁴ Division of Infectious Diseases, Department of Medicine, Stanford University, Stanford, CA, USA.
¹⁵ Division of Geographic Medicine and Infectious Diseases, Tufts Medical Center, Boston, MA, USA; Department of Public Health and Community Medicine, Tufts University School of Medicine, Boston, MA, USA; Tufts Center for Integrated Management of Antimicrobial Resistance, Tufts University School of Medicine, Boston, MA, USA.

PMID: 37716367
PMCID: PMC11060097
DOI: 10.1016/S2352-3018(23)00173-X

Review

Checklist for studies of HIV drug resistance prevalence or incidence: rationale and recommended use

Lawrence Mbuagbaw et al. Lancet HIV. 2023 Oct.

. 2023 Oct;10(10):e684-e689.

doi: 10.1016/S2352-3018(23)00173-X. Epub 2023 Sep 13.

Authors

Affiliations

¹ Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada; Department of Anesthesia, McMaster University, Hamilton, ON, Canada; Department of Pediatrics, McMaster University, Hamilton, ON, Canada; Biostatistics Unit, Father Sean O'Sullivan Research Centre, St Joseph's Healthcare, Hamilton, ON, Canada; Centre for Development of Best Practices in Health, Yaoundé Central Hospital, Yaoundé, Cameroon; Department of Global Health, Stellenbosch University, Cape Town, South Africa. Electronic address: mbuagblc@mcmaster.ca.
² Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada.
³ McGill Centre for Viral Diseases, Lady Davis Institute for Medical Research, Montréal, QC, Canada; Department of Microbiology and Immunology, McGill University, Montréal, QC, Canada; Department of Medicine, Surgery, and Infectious Disease, McGill University, Montréal, QC, Canada.
⁴ Hospital General de Agudos Dr. Cosme Argerich, Buenos Aires, Argentina; Helios Salud, Buenos Aires, Argentina.
⁵ Infectious Diseases Department, Fatouma Bourguiba University Hospital, Monastir, Tunisia.
⁶ Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada; Yale University School of Nursing, Yale University, West Haven, CT, USA; Centre for Urban Health Solutions, St Michael's Hospital, Toronto, ON, Canada.
⁷ HIV-1 Molecular Epidemiology Laboratory, Microbiology and Parasitology Department, Hospital Ramón y Cajal-IRYCIS and CIBEREsp-RITIP, Madrid, Spain.
⁸ Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel; Central Virology Laboratory, Ministry of Health and Sheba Medical Centre, Tel-Hashomer, Israel.
⁹ Data First Consulting, Sebastopol, CA, USA.
¹⁰ Department of Experimental Medicine, University of Rome 'Tor Vergata', Rome, Italy.
¹¹ Instituto Nacional de Enfermedades Respiratorias, Mexico City, Mexico; Centro de Investigaciones en Enfermedades Infecciosas, Mexico City, Mexico.
¹² Chantal BIYA International Reference Centre for Research on HIV/AIDS Prevention and Management, Yaoundé, Cameroon; Faculty of Health Science, University of Buea, Buea, Cameroon; National HIV Drug Resistance Working Group, Ministry of Public Health, Yaoundé, Cameroon.
¹³ Institute for Global Health, University College London, London, UK.
¹⁴ Division of Infectious Diseases, Department of Medicine, Stanford University, Stanford, CA, USA.
¹⁵ Division of Geographic Medicine and Infectious Diseases, Tufts Medical Center, Boston, MA, USA; Department of Public Health and Community Medicine, Tufts University School of Medicine, Boston, MA, USA; Tufts Center for Integrated Management of Antimicrobial Resistance, Tufts University School of Medicine, Boston, MA, USA.

PMID: 37716367
PMCID: PMC11060097
DOI: 10.1016/S2352-3018(23)00173-X

Abstract

HIV drug resistance (HIVDR) is a major challenge to the effectiveness of antiretroviral therapy. Global efforts in addressing HIVDR require clear, transparent, and replicable reporting in HIVDR studies. We describe the rationale and recommended use of a checklist that should be included in reports of HIVDR incidence and prevalence. After preliminary consultations with experts on HIVDR and establishing the need for guidance on HIVDR reporting, we used a sequential, explanatory, mixed methods approach to create the checklist; together with the accompanying articles, the checklist was reviewed by the authors and validated externally. The checklist for studies on HIVDR prevalence or incidence (CEDRIC-HIV) includes 15 recommended items that would enhance transparency and facilitate interpretation, comparability, and replicability of HIVDR studies. CEDRIC-HIV will help authors of HIVDR studies prepare research reports and assist reviewers and editors in assessments of completeness of reporting. The checklist will also facilitate statistical pooling and interpretation of HIVDR data.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests MMS declares receiving compensation from Theratechnologies, Janssen-Cilag, and ViiV Healthcare. RWS declares receiving compensation from Gilead Sciences, Vir Biotechnology, and GlaxoSmithKline. All other authors declare no competing interests.

References

1. UNAIDS. UNAIDS Fact sheet- World AIDS Day 2021. 2021. https://www.unaids.org/sites/default/files/media_asset/UNAIDS_FactSheet_... (accessed 10 February 2022).
1. Cambiano V, Rodger AJ, Phillips AN. ‘Test-and-treat’: the end of the HIV epidemic? Current opinion in infectious diseases 2011; 24(1): 19–26. - PubMed
1. Al-arydah Mt, Smith R. Adding Education to “Test and Treat”: Can We Overcome Drug Resistance? Journal of Applied Mathematics 2015; 2015: 781270.
1. WHO. Guidelines on the public health response to pretreatment HIV drug resistance. 2017. https://bit.ly/2C5GI7T.
1. Troyano-Hernáez P, Reinosa R, Holguín A. Genetic Diversity and Low Therapeutic Impact of Variant-Specific Markers in HIV-1 Pol Proteins. Front Microbiol 2022; 13: 866705. - PMC - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Grants and funding

R24 AI136618/AI/NIAID NIH HHS/United States

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Checklist for studies of HIV drug resistance prevalence or incidence: rationale and recommended use

Affiliations

Checklist for studies of HIV drug resistance prevalence or incidence: rationale and recommended use

Authors

Affiliations

Abstract

Conflict of interest statement

References

Publication types

MeSH terms

Grants and funding

LinkOut - more resources

Full Text Sources

Medical